FDA Requires Additional Trials For Catalyst Pharmaceuticals’ Rare Disease Drug

May 20, 2016

On www.xtalks.com - Just two months after Catalyst Pharmaceuticals received a rarely-issued Refuse to File letter from the US Food and Drug Administration (FDA), the biotech has faced more hurdles with the regulatory agency.

Spotlight

Alloga UK

Welcome to Alloga UK, a member of Walgreens Boots Alliance and the pan-European Alloga network. Alloga UK provide specialist logistics solutions to the UK Healthcare industry, offering specialist storage.

OTHER VIDEOS

Pharmacy Management System Project in Python Source Code

video | May 21, 2022

Pharmacy Management System Project in Python Source Code What is Pharmacy Management System Project in Python...

Watch Now

AI accelerated drug discovery

video | May 20, 2022

AI accelerated drug discovery, allowing for a fast-track discovery and repurposing of existing molecule, intelligent clinical design and coupled with in-house manufacturing....

Watch Now

Prescription Management System in SwilERP Pharmacy Software

video | May 27, 2022

Prescription Management is an essential task for the Pharmacist. The Prescription management feature of SwilERP Pharmacy Software enables the Pharmacists to create and maintain the medical records quickly and accurately evaluate the patient's health....

Watch Now

Accelerate Your Pharma 4.0 Journey with Our Manufacturing Execution Systems (MES) Solution

video | May 5, 2022

Today’s pharmaceutical manufacturers face increasing pressure to deliver high-quality medicines quickly, efficiently and economically while complying with regulatory requirements and meeting sustainability goals....

Watch Now